Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry.

@article{Ohashi2007RectalMF,
  title={Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry.},
  author={Toshio Ohashi and Atsunori Yorozu and Kazuhito Toya and Shiro Saito and Tetsuo Momma and Hirohiko Nagata and Michio Kosugi},
  journal={Japanese journal of clinical oncology},
  year={2007},
  volume={37 2},
  pages={121-6}
}
BACKGROUND To investigate rectal morbidity after I-125 prostate brachytherapy and to analyze predictive factors of rectal morbidity. METHODS A group of 227 consecutive patients with localized prostate cancer were treated with I-125 prostate brachytherapy with or without external beam radiotherapy (EBRT) between September 2003 and January 2005. Rectal morbidity (diarrhea, bleeding and pain) was evaluated using the Radiation Therapy Oncology Group (RTOG) criteria. Dosimetry was based on… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Five-year potency preservation after iodine-125 prostate brachytherapy

International Journal of Clinical Oncology • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…